GO Wales: Geniculate Artery Embolization for Knee Osteoarthritis: An End of Recruitment Update

Purpose: This trial aims to assess the effectiveness, tolerability, efficacy, and safety of geniculate artery embolization (GAE) in patients with mild to moderate osteoarthritis (OA) of the knee. An end of recruitment update to the trial is presented.

Materials and Methods: A prospective single arm feasibility trial was conducted with an aim to recruit 30–35 patients suffering from mild to moderate OA of the knee. The trial completed recruitment in November 2023 with recruitment of 31 patients. All patients will be followed-up for a total period of 2 years. Up-to-date Results of the efficacy of GAE in patients with knee OA using PROMs (Patient Reported Outcome Measures) is presented. Pain was recorded using VAS (Visual Analogue Score) and pain and quality of life was recorded using the Eq. 5D, Oxford Knee and WOMAC scores. Data regarding patients' tolerability and experience of this procedure was also collected using PREMs (Patient Reported Experience Measures).

Results: Patients exhibited a significant reduction in pain, with the Visual Analogue Scores improving from an average baseline of 68 to 38 at one month and 23 at 6 months. Quality of life metrics also showed improvement as evidenced by Eq. 5D, Oxford knee, and WOMAC scores. Notably, there were no adverse events related to the GAE procedure. Patients reported high tolerability and a positive overall experience with the GAE.

Conclusion: The end-of-recruitment update underscores the substantial improvement in pain and quality of life symptoms in patients undergoing GAE, as measured by VAS, Eq. 5D, OKS, and WOMAC scores. GAE emerges as a well-accepted and tolerated treatment option for knee OA.

Publikationsverlauf

Artikel online veröffentlicht:
02. April 2024